HC Wainwright Has Negative Estimate for Erasca Q3 Earnings

Key Points

• HC Wainwright lowered Erasca’s Q3 2026 EPS estimate to a loss of $0.14 per share from $0.13, while maintaining a “Buy” rating and a $22 price target.
• Erasca reported a quarterly loss of $0.14 per share, missing the consensus estimate of a $0.11 loss by $0.03. Analysts’ overall view remains a “Moderate Buy,” with a consensus price target of $21.91.
• Erasca shares opened at $17.86 after falling 3.9%; the clinical-stage biotech has a $6.25 billion market capitalization, and institutional investors own 67.78% of its stock.

Erasca, Inc. (NASDAQ:ERAS - Free Report) - Analysts at HC Wainwright reduced their Q3 2026 EPS estimates for shares of Erasca in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.14) per share for the quarter, down from their previous forecast of ($0.13). HC Wainwright has a "Buy" rating and a $22.00 price target on the stock. The consensus estimate for Erasca's current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for Erasca's Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.51) EPS, FY2027 earnings at ($0.58) EPS, FY2028 earnings at ($0.61) EPS, FY2029 earnings at ($0.70) EPS and FY2030 earnings at ($0.54) EPS.

Several other equities analysts also recently issued reports on the stock. Wolfe Research set a $16.00 price target on shares of Erasca in a research note on Thursday, June 4th. Guggenheim increased their price objective on Erasca from $20.00 to $21.00 and gave the company a "buy" rating in a report on Thursday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Erasca in a research report on Thursday, June 11th. Bank of America lifted their target price on Erasca from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Tuesday, July 14th. Finally, Morgan Stanley upped their price target on Erasca from $12.00 to $21.00 and gave the company an "equal weight" rating in a research report on Monday, July 20th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $21.91.

Erasca Stock Down 3.9%

Shares of ERAS opened at $17.86 on Friday. Erasca has a 12-month low of $1.33 and a 12-month high of $24.28. The business has a 50-day simple moving average of $17.18 and a two-hundred day simple moving average of $15.00. The stock has a market cap of $6.25 billion, a PE ratio of -18.80 and a beta of 0.66.

Erasca (NASDAQ:ERAS - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03).

Hedge Funds Weigh In On Erasca

Hedge funds have recently bought and sold shares of the company. Spruce Street Capital LP acquired a new position in Erasca in the second quarter valued at $7,740,988,000. Sanctuary Advisors LLC acquired a new stake in Erasca during the 2nd quarter worth about $212,000. Polymer Capital Management HK LTD acquired a new stake in Erasca during the 2nd quarter worth about $8,757,000. Quantbot Technologies LP bought a new position in shares of Erasca in the 2nd quarter worth about $106,000. Finally, Allworth Financial LP acquired a new position in shares of Erasca in the 2nd quarter valued at about $34,000. Institutional investors own 67.78% of the company's stock.

Erasca Company Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca's approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca's pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source